Why pre-commercial biotech companies build their commercial presence 18 months too late

Most pre-commercial biotech companies believe their Phase 2 data will do the talking. The BD leads who could sign their licensing deal have already moved on. Not because the science wasn't good enough. Because they had never heard of the company.

The logic behind "we'll market after the data"

It's a reasonable position. You're a scientist. You believe in evidence. You have maybe eight people in the company, a runway you're protecting, and a CMC package that needs more attention than your LinkedIn profile. Marketing feels like something for commercial-stage companies: the ones with a product to sell, a launch to plan, a sales team to arm.

More than that, there's a cultural dimension in much of the biotech world. You let the science speak. You don't self-promote before you've earned it. Aggressive commercial posturing before Phase 2 data looks desperate in a room full of people who can read a forest plot.

This logic is not wrong. It just stops at the wrong conclusion.

The problem isn't that early-stage biotech companies value scientific substance over marketing noise. The problem is that they've conflated "not doing marketing" with "not being commercially visible." Those are very different things.

What partnership conversations actually require before the data arrives

Business development at large pharma and mid-sized biotech works on long cycles. The people evaluating your asset in 2027 have been building their watchlist since 2024. They are not browsing the scientific literature looking for surprises. They are tracking companies and programs they've already identified as interesting. You need to be interesting to them before you have anything to sell.

Pharma companies with top-quartile sourcing networks identify licensing targets 6 to 8 months earlier than their competitors, according to Vision Lifesciences' 2026 Biotech Licensing Deal Tracker. That gap compounds: by the time a mid-tier pharma company becomes aware of your program, the strategic players may have already completed initial due diligence and formed a view.

Once formal discussions begin, deals themselves take anywhere from 6 weeks to 12 months to close depending on complexity, according to Novartis's published BD process guidance. The implication is clear: the window for building awareness needs to open well before you think you are ready for partnership conversations.

What does "visibility" actually mean in biotech BD conversations?

Visibility in this context is not about follower counts. It is about being a recognisable name in a specific therapeutic conversation. When a BD lead at a mid-sized pharma company opens their notes before a partnering meeting, they should already know three things: who you are, what you're working on, and roughly where you sit in the competitive landscape. All three require a consistent, specific commercial presence that predates the meeting by a significant margin.

The companies that achieve this aren't doing aggressive marketing. They are doing precise, consistent activity across a small number of channels: scientific conference presence, LinkedIn posts from key people in the company, and an occasionally updated website that actually reflects current science. That's not a large operation. It is, however, a deliberate one. And it needs to start earlier than most founders believe.

The window that matters is typically 12 to 18 months before you expect to enter serious partnership conversations. If your Phase 2 readout is expected in late 2026, the work to be commercially visible starts in early 2025. Not with a commercial team. Not with a marketing agency. With a founder who posts on LinkedIn twice a month and a company that shows up consistently at three or four conferences a year.

The gap between scientific output and commercial presence

There is a structural reason most early-stage biotechs fall behind on this, and it's not lack of effort. It's a staffing problem that's entirely rational.

The first commercial hire at most pre-clinical and clinical-stage biotech companies happens at Series B or later, sometimes not until 12 months before anticipated launch. Until then, the people in the building are scientists. They are world-class at what they do, and what they do is science. Commercial presence-building sits in a gap between their job description and anyone else's.

The result is a pattern that repeats consistently across the industry. A company with genuinely competitive science enters partnering conversations at Bio-Europe, Nordic Life Science Days, BIO International, or JPMorgan. They discover that the people they most need to meet have already formed a view of them. Often it's a thin view, assembled from fragments: a conference abstract from two years ago, a website that still lists the founding team without any pipeline update, a LinkedIn company page with 87 followers and the last post from Q3 of the previous year.

This is not a fatal problem. But it is a self-inflicted one, and it is entirely preventable.

What companies that get this right do differently

The companies that build commercial visibility effectively before they have commercial resources share three behaviors.

They treat scientific communication as commercial infrastructure, not PR.

When a key opinion leader cites your product in a paper, that's not just a validation of your science. It's a signal in a commercial network. When your CEO presents at a symposium, the slides that go up on the conference website are commercial content. The companies that get this right are deliberate about how they participate in scientific conversations, knowing that those conversations are also commercial ones.

They pick a very small number of channels and maintain them consistently.

Not a blog, a newsletter, a Twitter account, LinkedIn, an events calendar, and a podcast. One or two channels, updated regularly, by people with enough seniority that the content actually carries weight. For most pre-commercial biotechs, this means LinkedIn (specifically the founder or CSO's personal account) and consistent physical presence at four to six high-relevance conferences per year.

The companies that do this well have also built an internal system for it, because consistency without a system collapses the moment the CEO is consumed by an IND filing or a board meeting. The system doesn't need to be elaborate. It needs to be reliable enough that commercial visibility doesn't disappear for six months whenever something important happens in the lab.

They start before they feel ready.

This is the one that is hardest to act on. There will never be a moment where the science is settled enough, the data mature enough, the story polished enough to feel like the right time. The companies that build strong commercial presence before launch started posting about their science before they were comfortable doing it. And they were judicious, not reckless, about what they shared.

The threshold for starting isn't "we have something to announce." It's "we have a point of view worth sharing": about the therapeutic area, about a mechanism of action, about a conference they attended, about a paper that changes how they think about their program. That threshold is much lower, and most founding teams cross it every week without realizing it.

Why Smaller Ecosystems Make This More Urgent, Not Less

In large biotech hubs like Boston, the Bay Area, or San Diego, a company can emerge from relative obscurity with strong Phase 2 data and attract serious interest within a compressed timeframe. The ecosystem is large enough that surprises happen.

In smaller, more interconnected ecosystems (whether that's Medicon Valley, the emerging clusters in Benelux, or single-country markets across Europe and Asia) the network already knows who you are, or it doesn't. Reputation is built more slowly and is harder to correct once formed. The companies that have been consistently showing up in the right conversations, at the right events, with the right scientific content are not just more visible. They're more trusted. And trust, in biotech BD, is the currency that determines who gets the second meeting.

This means the 18-month timing problem is more consequential for companies operating outside the major US hubs than it is for companies inside them. The buffer that comes from being in a high-density network of potential partners and investors doesn't exist in the same way. You have to build presence more deliberately, and you have to start earlier.

The biotech sector produces exceptional science. The commercial infrastructure that gets that science to patients, through partnerships, licensing deals, acquisitions, and eventually launches, depends on relationships and reputations that take years to build. The companies that understand this start earlier than they think they need to, in smaller and more deliberate ways than they imagined, and they build the internal systems that make consistency possible even when everyone is busy doing the science.

The 18-month gap isn't a marketing problem. It's a timing problem. And unlike most problems in drug development, this one has a straightforward solution: start the clock earlier.

Pyroplane is a content operations and marketing calendar built for life sciences commercial teams. If you're figuring out how to build and maintain a consistent commercial presence with a small team, it's worth a look.

Sources:

• Vision Lifesciences, *Biotech Licensing Deal Tracker 2026* — data on BD sourcing windows and competitive identification timelines

  
  

• Drug Discovery World, "The Art of Collaboration: Partnering and Licensing at Novartis" — deal closure timeline ranges

  
  

• BioPharma Dive, "Facing uncertainty on steroids, biotech dealmakers tread more cautiously" (May 2025) — current deal cycle durations